| Literature DB >> 34718049 |
Fumihiko Ueno1, Yusuke Iwata2, Shinichiro Nakajima3, Fernando Caravaggio4, Jose M Rubio5, Guillermo Horga6, Clifford M Cassidy7, Edgardo Torres-Carmona8, Vincenzo de Luca9, Sakiko Tsugawa10, Shiori Honda10, Sho Moriguchi10, Yoshihiro Noda10, Philip Gerretsen11, Ariel Graff-Guerrero12.
Abstract
Although schizophrenia is associated with increased presynaptic dopamine function in the striatum, it remains unclear if neuromelanin levels, which are thought to serve as a biomarker for midbrain dopamine neuron function, are increased in patients with schizophrenia. We conducted a systematic review and meta-analysis of magnetic resonance imaging (MRI) and postmortem studies comparing neuromelanin (NM) levels between patients with schizophrenia and healthy controls (HCs). Standard mean differences were calculated to assess group differences in NM accumulation levels between patients with schizophrenia and HCs. This study included 7 articles in total. Five studies employed NM-sensitive MRI (NM-MRI) and two were postmortem brain studies. The patient group (n = 163) showed higher NM levels in the substantia nigra (SN) than HCs (n = 228) in both the analysis of the seven studies and the subgroup analysis of the 5 NM-MRI studies. This analysis suggest increased NM levels in the SN may be a potential biomarker for stratifying schizophrenia, warranting further research that accounts for the heterogeneity of this disorder.Entities:
Keywords: Dopamine; NM-MRI; Neuromelanin; Review; Schizophrenia; Substantia nigra
Mesh：
Substances：
Year: 2021 PMID： 34718049 PMCID： PMC9059704 DOI： 10.1016/j.neubiorev.2021.10.028
Source DB: PubMed Journal: Neurosci Biobehav Rev ISSN： 0149-7634 Impact factor: 9.052